Free Trial
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
uniQure N.V. stock logo
QURE
uniQure
$22.66
-3.4%		$43.30
$8.73
▼
$71.50
$1.57B1.062.46 million shs1.33 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
uniQure N.V. stock logo
QURE
uniQure
0.00%-38.63%-47.28%-43.28%-57.28%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
uniQure N.V. stock logo
QURE
uniQure
$22.66
-3.4%		$43.30
$8.73
▼
$71.50
$1.57B1.062.46 million shs1.33 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
uniQure N.V. stock logo
QURE
uniQure
0.00%-38.63%-47.28%-43.28%-57.28%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
uniQure N.V. stock logo
QURE
uniQure
2.75
Moderate Buy$53.73137.15% Upside

Current Analyst Ratings Breakdown

Latest QURE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/5/2026
uniQure N.V. stock logo
QURE
uniQure
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$60.00 ➝ $28.00
10/2/2026
uniQure N.V. stock logo
QURE
uniQure
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$65.00 ➝ $48.00
9/30/2026
uniQure N.V. stock logo
QURE
uniQure
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$46.00 ➝ $31.00
9/29/2026
uniQure N.V. stock logo
QURE
uniQure
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$75.00
9/29/2026
uniQure N.V. stock logo
QURE
uniQure
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/23/2026
uniQure N.V. stock logo
QURE
uniQure
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/21/2026
uniQure N.V. stock logo
QURE
uniQure
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
9/2/2026
uniQure N.V. stock logo
QURE
uniQure
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold ➝ Outperform
7/30/2026
uniQure N.V. stock logo
QURE
uniQure
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$65.00 ➝ $60.00
7/30/2026
uniQure N.V. stock logo
QURE
uniQure
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$60.00 ➝ $75.00
(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
uniQure N.V. stock logo
QURE
uniQure
$16.10M97.61N/AN/A$3.19 per share7.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
uniQure N.V. stock logo
QURE
uniQure
-$198.97M-$4.01N/AN/AN/A-1,350.73%-111.96%-29.01%11/9/2026 (Estimated)

Latest QURE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2026Q2 2026
uniQure N.V. stock logo
QURE
uniQure
-$0.8223-$1.22-$0.3977-$1.22$5.45 million$5.84 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
uniQure N.V. stock logo
QURE
uniQure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
uniQure N.V. stock logo
QURE
uniQure
0.15
10.01
10.01

Institutional Ownership

CompanyInstitutional Ownership
uniQure N.V. stock logo
QURE
uniQure
78.83%

Insider Ownership

CompanyInsider Ownership
uniQure N.V. stock logo
QURE
uniQure
4.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
uniQure N.V. stock logo
QURE
uniQure
22169.37 million66.14 millionOptionable

Recent News About These Companies

uniQure (NASDAQ:QURE) Shares Gap Down on Analyst Downgrade
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-uniqure-nasdaq-qure-shares-gap-down-on-analyst-downgrade-2026-10-05/
uniQure (NASDAQ:QURE) Rating Lowered to "Equal Weight" at Barclays
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31086944
uniQure (NASDAQ:QURE) Cut to Equal Weight at Barclays
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-uniqure-nasdaq-qure-cut-to-equal-weight-at-barclays-2026-10-05/
Barclays Sticks to Their Buy Rating for uniQure (QURE)
October 4 at 3:09 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/QURE/pressreleases/4898440/barclays-sticks-to-their-buy-rating-for-uniqure-qure/
RBC Cuts Price Target on uniQure to $48 From $65, Keeps Outperform, Speculative Risk
October 2 at 8:58 AM  |  marketscreener.comM
uniQure (NASDAQ:QURE) Shares Climb 6.9% - Should You Buy?
October 2 at 6:40 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31078296
Top Small Cap Stocks To Watch Now - September 29th
October 2 at 6:03 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31078218
10 Stocks With Massive Short Squeeze Potential
October 1, 2026  |  schaeffersresearch.comhttps://www.schaeffersresearch.com/content/analysis/2026/10/01/10-stocks-with-massive-short-squeeze-potential
uniQure (QURE) Stock Plunges 48% After Huntington’s Drug Data Miss
October 1, 2026  |  coincentral.comC
uniQure (QURE) Faces A Fresh AMT 130 Test After Mixed Data, Bargain Or Trap
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/uniqure-qure-faces-fresh-amt-050903433.html
uniQure (NASDAQ:QURE) Stock Sees Heavy Call Option Buying
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31072903
UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights
September 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/30/3372463/937/en/uniqure-investigation-qure-securities-investors-encouraged-to-contact-kirby-mcinerney-llp-about-their-rights.html
uniQure Plunges on Additional Data From Huntington's Disease Study
September 30, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2998447/uniqure-plunges-on-additional-data-from-huntington-s-disease-study?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2998447
uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update
September 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4951094-uniqure-a-speculative-buy-after-huntingtons-disease-trial-4-year-data-update?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update
September 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4951094-uniqure-a-speculative-buy-after-huntingtons-disease-trial-4-year-data-update
uniQure (NASDAQ:QURE) Shares Climb 6.9% - What's Next?
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-uniqure-nasdaq-qure-shares-climb-69-whats-next-2026-09-30/
uniQure Stock Crashed on Its Huntington’s Data. Wall Street’s Price Target Says the Selloff Went Too Far
September 30, 2026  |  247wallst.comhttps://247wallst.com/investing/2026/09/30/uniqure-stock-crashed-on-its-huntingtons-data-wall-streets-price-target-says-the-selloff-went-too-far/
uniQure Stock Crashed on Its Huntington's Data. Wall Street's Price Target Says the Selloff Went Too Far
September 30, 2026  |  247wallst.comhttps://247wallst.com/investing/2026/09/30/uniqure-stock-crashed-on-its-huntingtons-data-wall-streets-price-target-says-the-selloff-went-too-far/?utm_source=snapi
uniQure Stock Plunges On 4-Year Data, But The Approval Path Is Intact (Rating Upgrade)
September 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4950990-uniqure-stock-plunges-on-4-year-data-but-the-approval-path-is-intact-upgrade?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
uniQure tanks is it reports new data from Phase I/II studies of ifezuntirgene inilparvovec
September 30, 2026  |  thepharmaletter.comT
uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish
September 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4950775-uniqure-another-selloff-on-48-month-huntington-data-i-am-marginally-bullish

New MarketBeat Followers Over Time

Media Sentiment Over Time

uniQure stock logo

uniQure NASDAQ:QURE

$22.66 -0.81 (-3.43%)
As of 11:37 AM Eastern
This is a fair market value price provided by Massive. Learn more.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas